Effect of Nonautonomic Drugs on the Vesical Neck

Khanna, Om P.

doi:10.1007/978-1-4612-5476-8_35

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1991

2011

Publication Types

Select...

Article4

Book1

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 5 publications

(1 citation statement)

References 120 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Through effects on detrusor muscle and urinary sphincter function, several categories of prescription drugs can worsen LUTS, 2,3 including antidepressants, antihistamines, bronchodilators, anticholinergics and sympathomimetics. 4 By increasing urine volume, diuretics are also associated with LUTS.…”

mentioning

confidence: 99%

Contribution of Common Medications to Lower Urinary Tract Symptoms in Men

et al. 2011

View full text Add to dashboard Cite

mentioning

confidence: 99%

Contribution of Common Medications to Lower Urinary Tract Symptoms in Men

et al. 2011

View full text Add to dashboard Cite

Atamestane, a New Aromatase Inhibitor for the Management of Benign Prostatic Hyperplasia

ETREBY,

NISHINO,

HABENICHT

et al. 1991

Journal of Andrology

View full text Add to dashboard Cite

Atamestane is a new, competitive, and irreversible inhibitor of estrogen biosynthesis. Its pharmacologic action has been evaluated in mice, rats, rabbits, dogs, monkeys, and humans. In rats, atamestane leads to a decrease of pregnant mare serum gonadotropin‐stimulated ovarian estrogen production, and inhibits androstenedione‐induced estrogenic effects such as uterine growth and abortion. In all species tested, atamestane lacks other intrinsic hormonal or antihormonal activities, and shows no inhibition of other cytochrome P450‐dependent enzymes of adrenal steroidogenesis. However, it inhibits estrogen‐related negative feedback. The extent and consequences of the induced counterregulation of the pituitary‐hypothalamic axis show major sex‐ and species‐specific differences. Atamestane is highly effective in inhibiting estrogen‐induced hyperplastic changes in the fibromuscular stroma of the prostate in androstenedione‐treated dogs and monkeys. In male volunteers and patients with benign prostatic hyperplasia (BPH), atamestane induces an expected reduction of serum (and BPH tissue) estrogen concentrations without significant changes in androgen levels. In conclusion, all available results indicate that atamestane is a selective (no inhibition of adrenal function), pure (no endocrine side effects), and highly effective steroidal aromatase inhibitor, with an excellent safety profile. Based on the discussion of its clinical potential, atamestane seems to be a promising compound for the management of BPH.

show abstract

Effects of Estrogens on the Prostate

THOMAS,

KEENAN

1994

Journal of Andrology

View full text Add to dashboard Cite

Effect of Nonautonomic Drugs on the Vesical Neck

Cited by 5 publications

References 120 publications

Contribution of Common Medications to Lower Urinary Tract Symptoms in Men

Contribution of Common Medications to Lower Urinary Tract Symptoms in Men

Atamestane, a New Aromatase Inhibitor for the Management of Benign Prostatic Hyperplasia

Effects of Estrogens on the Prostate

Contact Info

Product

Resources

About